EP2983791A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Google Patents
METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASESInfo
- Publication number
- EP2983791A4 EP2983791A4 EP14782473.4A EP14782473A EP2983791A4 EP 2983791 A4 EP2983791 A4 EP 2983791A4 EP 14782473 A EP14782473 A EP 14782473A EP 2983791 A4 EP2983791 A4 EP 2983791A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- treatment
- methods
- autoimmune diseases
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361853745P | 2013-04-11 | 2013-04-11 | |
| PCT/US2014/033872 WO2014169255A1 (en) | 2013-04-11 | 2014-04-11 | Methods and compositions of treating autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2983791A1 EP2983791A1 (en) | 2016-02-17 |
| EP2983791A4 true EP2983791A4 (en) | 2016-11-09 |
Family
ID=51690049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14782473.4A Withdrawn EP2983791A4 (en) | 2013-04-11 | 2014-04-11 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10426794B2 (en) |
| EP (1) | EP2983791A4 (en) |
| CN (1) | CN105307725B (en) |
| BR (1) | BR112015026019A2 (en) |
| CA (1) | CA2918196A1 (en) |
| WO (1) | WO2014169255A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN108129554A (en) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | Erythrocyte binding therapeutic agent |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| SG10202010936RA (en) | 2014-02-21 | 2020-12-30 | Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
| EP3416624B8 (en) | 2016-02-18 | 2023-08-23 | Cour Pharmaceuticals Development Company Inc. | Process for the preparation of tolerizing immune-modulating particles |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| WO2018065622A1 (en) | 2016-10-07 | 2018-04-12 | Secarna Pharmaceuticals Gmbh & Co Kg | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39 |
| EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN112384204B (en) | 2018-02-26 | 2023-03-14 | 安托瑞斯公司 | Tolerogenic liposomes and methods of use thereof |
| CN112384239A (en) | 2018-05-09 | 2021-02-19 | 芝加哥大学 | Compositions and methods for affecting immune tolerance |
| WO2019236593A1 (en) * | 2018-06-05 | 2019-12-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells |
| US20230399376A1 (en) * | 2019-05-27 | 2023-12-14 | Baker Heart and Diabetes Institute | Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases |
| EP4359084A4 (en) * | 2021-06-22 | 2025-10-08 | Univ Columbia | NEW mRNA VACCINE FOR AUTOIMMUNITY |
| CN114931633B (en) * | 2022-06-10 | 2025-07-04 | 苏州尔生生物医药有限公司 | Preparation method and application of autoimmune disease vaccine derived from pre-activated antigen presenting cells |
| CN120192922A (en) * | 2025-05-26 | 2025-06-24 | 华中科技大学同济医学院附属同济医院 | In vitro induced tolerant dendritic cells and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066088A2 (en) * | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
| WO2010072797A1 (en) * | 2008-12-22 | 2010-07-01 | The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Compounds and methods for the treatment of autoimmune and inflammatory disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060291A2 (en) * | 2002-12-31 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| WO2008024299A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| CA2671697A1 (en) * | 2006-12-07 | 2008-06-12 | Schering Corporation | Use of il-27 agonists to reduce immune mediated abortion |
| EP2591804A3 (en) | 2007-09-24 | 2014-04-16 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| JP2011503104A (en) * | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | Immunomodulatory compounds and related compositions and methods |
| MX340972B (en) * | 2008-10-08 | 2016-08-02 | Intrexon Corp | CELLS MANIPULATED BY ENGINEERING THAT EXPRESS MULTIPLE IMMUNOMODULATORS, AND USE OF THE SAME. |
| EP2413958A4 (en) | 2009-03-31 | 2014-04-02 | Univ East Carolina | CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES |
| AU2011268146A1 (en) * | 2010-06-17 | 2013-01-10 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
-
2014
- 2014-04-11 BR BR112015026019A patent/BR112015026019A2/en not_active Application Discontinuation
- 2014-04-11 EP EP14782473.4A patent/EP2983791A4/en not_active Withdrawn
- 2014-04-11 CA CA2918196A patent/CA2918196A1/en not_active Abandoned
- 2014-04-11 CN CN201480033535.7A patent/CN105307725B/en not_active Expired - Fee Related
- 2014-04-11 US US14/783,679 patent/US10426794B2/en active Active
- 2014-04-11 WO PCT/US2014/033872 patent/WO2014169255A1/en not_active Ceased
-
2019
- 2019-09-30 US US16/588,234 patent/US20200069731A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006066088A2 (en) * | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
| WO2010072797A1 (en) * | 2008-12-22 | 2010-07-01 | The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Compounds and methods for the treatment of autoimmune and inflammatory disease |
Non-Patent Citations (5)
| Title |
|---|
| B. M. MATTA ET AL: "IL-27 Production and STAT3-Dependent Upregulation of B7-H1 Mediate Immune Regulatory Functions of Liver Plasmacytoid Dendritic Cells", THE JOURNAL OF IMMUNOLOGY, vol. 188, no. 11, 16 April 2012 (2012-04-16), US, pages 5227 - 5237, XP055306344, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1103382 * |
| D. C. FITZGERALD ET AL: "Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis", THE JOURNAL OF IMMUNOLOGY, vol. 179, no. 5, 20 August 2007 (2007-08-20), US, pages 3268 - 3275, XP055306398, ISSN: 0022-1767, DOI: 10.4049/jimmunol.179.5.3268 * |
| IVAN D MASCANFRONI ET AL: "IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39", NATURE IMMUNOLOGY, vol. 14, no. 10, 1 September 2013 (2013-09-01), GB, pages 1054 - 1063, XP055306298, ISSN: 1529-2908, DOI: 10.1038/ni.2695 * |
| IVAN D MASCANFRONI ET AL: "New Pieces in the Puzzle How Does Interferon-? Really Work in Multiple Sclerosis?", ANNALS OF NEUROLOGY, vol. 65, no. 5, 1 May 2009 (2009-05-01), pages 487 - 488, XP055306333 * |
| See also references of WO2014169255A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200069731A1 (en) | 2020-03-05 |
| US10426794B2 (en) | 2019-10-01 |
| CN105307725A (en) | 2016-02-03 |
| WO2014169255A1 (en) | 2014-10-16 |
| CA2918196A1 (en) | 2014-10-16 |
| EP2983791A1 (en) | 2016-02-17 |
| US20160058792A1 (en) | 2016-03-03 |
| BR112015026019A2 (en) | 2017-07-25 |
| CN105307725B (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1011I2 (en) | PRODRUGS OF FUMARATES AND THEIR USE FOR THE TREATMENT OF VARIOUS DISEASES | |
| EP2983791A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3448875A4 (en) | COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| EP3370703A4 (en) | COMBINATION OF GEMCABEN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| EP3389672A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASES | |
| MA43283A (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES | |
| EP2872151A4 (en) | ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | |
| EP3341391A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN | |
| EP2953950A4 (en) | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | |
| EP2968133A4 (en) | TOPICAL COMPOSITIONS AND METHODS OF TREATING TOPICAL DISORDERS | |
| EP2800579A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES | |
| EP2967062A4 (en) | DEETHYLHYDROXYCHLOROQUINE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION | |
| EP2741771A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | |
| EP3316887A4 (en) | GLS1 INHIBITORS FOR THE TREATMENT OF DISEASES | |
| EP2922534A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| FR3017298B1 (en) | CONJUGATES AND PRO-DRUGS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
| EP3344258A4 (en) | TREATMENT OF AUTOIMMUNE DISEASES AND SELF-INFLAMMATORY DISEASES | |
| EP2968478A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA | |
| EP2879620A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE EMIDIES AND OPEN FRACTURES | |
| EP2830644A4 (en) | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEUROPATHY | |
| EP3395341A4 (en) | COMPOSITION FOR THE TREATMENT OF NEUROMITRIC DISEASES AND USE THEREOF | |
| EP2544686A4 (en) | COMBINED METHODS FOR THE TREATMENT OF DISEASES | |
| EP2968435A4 (en) | PEPTIDES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP2863939A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VITILIGO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20151111 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: QUINTANA, FRANCISCO J. Inventor name: MASCANFRONI, IVAN D. |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20161010 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/06 20060101AFI20161004BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20180305 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20221101 |